The SafeDESIgn imaging-based toxicity reporter platform for chemical safety assessment

Tuesday 28 January 2020

10.00-10.45 am EST, 16-16.45 CET - (7 am California, 10 am New York, 15.00 London, 16.00 Zurich, 20.30 New Delhi, 24.00 Tokyo)

Signup here

This virtual meeting will include a perspective and a discussion session. 

High drug attrition rates are the main cause for the (exponentially) increasing healthcare cost. The lack of predictive in vitro models to either accurately test drug efficacy or determine toxic side effects in an early phase of drug development is causing this high failure rate. At Leiden University we developed the innovative SafeDESIgn reporter platform that we use to accurately assess the efficacy and/or safety of chemicals. The generated fluorophore reporter cell lines can be imaged with a confocal microscope over time so that we can accurately quantify the early dynamic adaptive signaling changes. By doing so we can not only determine if a chemical at a certain concentration is toxic, but also which adaptive/adverse pathways are activated. This is crucial information if we want to predict human safety levels for these chemicals.

Over the last couple of years we further developed the system improving the throughput and robustness. Besides the standard 2D culturing method, the reporters can also be cultured in 3D allowing for repeated dosing in a more differentiated liver spheroid system. Currently we are commercializing the technology in a Leiden University CRO based spin-off called “DESI” (Drug efficacy & Safety Imaging). In the webinar we will further explain the reporter platform, show some neat fluorophore time-lapse movies, give some examples of how we applied the technology in some industrial case studies and there will be plenty of time for discussion and Q&A.

Latest Tweets

Edelweiss Connect (5 weeks ago)
Read our latest #SaferWorldbydesign newsletter highlighting SaferSkin™ new features and products. #SaferSkin… https://t.co/z9SmrlJ3Yb
Edelweiss Connect (5 weeks ago)
Curation of drug-induced mechanistic toxicological processes and adverse outcome pathway in (DILI) Presented by Cu… https://t.co/8n0QoR3gXa
Edelweiss Connect (5 weeks ago)
The approach may be further extended by additional in silico and in vitro methods to strengthen the weight of evide… https://t.co/oLCdYGMTnW
Edelweiss Connect (5 weeks ago)
Our #SaferSkin™ app implements three well-adopted approaches to perform an integrated analysis of the OECD-approved… https://t.co/MA7DY0RdwO
Edelweiss Connect (6 weeks ago)
#SaferWorldbyDesign & @MultiCASEInc present: Use of in silico methods for assessing toxicity #QSAR #insilico… https://t.co/AgoolrhT7M

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA